Fractyl Health Announced Single Administration Of Rejuva Reduced Fat Mass And Improved Glycemia In The Well-validated Diet-induced Obesity Mouse Model

Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today presented new data from its preclinical Rejuva pancreatic gene therapy program in an oral presentation at the American Diabetes Association (ADA)'s 84th Scientific Sessions in Orlando, FL. The presentation titled "Single-Dose GLP-1-Based Pancreatic Gene Therapy Durably Maintains Body Composition and Glycemia After Semaglutide Withdrawal in a Murine Model of Obesity," and was chosen as noteworthy and one of eight President's Select Abstracts at ADA this year.

Single administration of Rejuva reduced fat mass and improved glycemia in the well-validated diet-induced obesity (DIO) mouse model

Rejuva also prevented weight and glycemic rebound after semaglutide withdrawal

Data provide first demonstration that Rejuva treatment has potential to mimic natural release of GLP-1 from pancreas